Tanya Siddiqi, MD
Hematology · Duarte, CANPI 1467408948
Payments from drug & device makers
What this record shows
The money is spread across several categories — consulting fees (46.1%), speaking fees and travel and lodging — rather than concentrated in one kind of arrangement. 16 manufacturers reported payments, led by AstraZeneca at 26.8% of the total. Reporting peaked in 2019 at $47,638 and has fallen 89.8% since, to $4,859 in 2025. Among hematology clinicians in CA with any reported payments, this total sits in the top 10% — high for the specialty, which is a reason to read the composition above rather than the number alone.
Across 168 payments — averaging $1184.44 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.
- AstraZeneca$53K
- Bristol Myers Squibb$48K
- Beigene USA, Inc.$22K
- AbbVie$22K
- Pharmacyclics LLC, An Abbvie Company$21K
- E.r. Squibb & Sons, L.L.C.$17K
- plus $15K from 10 others
Across 372 payments — averaging $50,051 each. Payments tied to a research study. These frequently flow through the physician to a hospital or research institution rather than to the physician personally.
- Bristol Myers Squibb$7.8M
- AbbVie$4.6M
- Beigene, Ltd.$2.4M
- E.r. Squibb & Sons, L.L.C.$2.3M
- TG Therapeutics, Inc.$452K
- Pharmacyclics LLC, An Abbvie Company$406K
- plus $771K from 9 others
What the payments were for
- Consulting fees$91,75746%
- Speaking & faculty fees$64,34132%
- Travel & lodging$38,13619%
- Food & beverage$4,7512%
General payments by program year
Who reported the general payments
Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.
| Company | Payments | Total |
|---|---|---|
| AstraZeneca(2 entities) | 58 | $53,381 |
| Bristol Myers Squibb | 21 | $48,303 |
| Beigene USA, Inc. | 16 | $22,403 |
| AbbVie | 19 | $21,763 |
| Pharmacyclics LLC, An Abbvie Company | 21 | $20,896 |
| E.r. Squibb & Sons, L.L.C. | 9 | $16,832 |
| Genmab U.S., Inc. | 5 | $5,573 |
| Gilead | 4 | $3,133 |
| Innate Pharma, Inc | 1 | $2,400 |
| Beone Medicines USA, Inc. | 1 | $2,400 |
| Seagen Inc. | 3 | $1,425 |
| Genentech USA, Inc. | 4 | $195 |
| Morphosys, US Inc. | 1 | $138 |
| Johnson & Johnson | 3 | $85 |
| Astrazeneca UK Limited | 1 | $45 |
| Pfizer | 1 | $14 |
What the payments were tied to
Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.
How this compares
$198,985 in reported general payments places this provider in the 90th percentile of 178 hematology providers in California.
Medicare billing
What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.
Most prescribed under Part D
| Drug | Claims | Cost to plans & patients |
|---|---|---|
| BrukinsaZanubrutinib | 81 | $970,674 |
| JaypircaPirtobrutinib | 34 | $752,729 |
| VenclextaVenetoclax | 70 | $606,348 |
| CalquenceAcalabrutinib Maleate | 25 | $360,727 |
| ImbruvicaIbrutinib | 14 | $219,738 |
| Acyclovir | 32 | $221 |
| Allopurinol | 41 | $220 |
| Prednisone | 17 | $60 |
Paid to pharmacies, not to this prescriber.
Companies that both paid and supply prescribed drugs
These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.
| Company | Paid to this provider | Part D cost of their drugs |
|---|---|---|
| Beigene USA, Inc.Brukinsa | $22,403 | $970,67481 claims |
| AbbVieVenclexta | $21,763 | $606,34870 claims |
| AstraZenecaCalquence | $53,381 | $360,72725 claims |
| Pharmacyclics LLC, An Abbvie CompanyImbruvica | $20,896 | $219,73814 claims |
Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 90th percentile of 178 hematology providers in California.
Other hematology in Duarte
- Amrita KrishnanDuarte$671K
- Vinod PullarkatDuarte$576K
- Alexey DanilovDuarte$407K
- Tycel PhillipsDuarte$348K
- Haris AliDuarte$310K
- Amandeep SalhotraDuarte$214K
- Scott GoldsmithDuarte$180K
- Ibrahim AldossDuarte$175K
- Alex HerreraDuarte$155K
- Geoffrey ShouseDuarte$143K
Where these figures come from
- Payments: CMS Open Payments, program years 2019–2025 (publication P06302026_06032026).
- Billing: Medicare Physician & Other Practitioners, data year 2024. Original Medicare Part B only.
- Identity: NPPES NPI Registry, July 2026.